Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Ørntoft, NW, Blé, M, Baiges, A, Ferrusquia, J, Hernández-Gea, V, Turon, F, Magaz, M, Møller, S, Møller, HJ, Garcia-Pagan, JC & Gronbaek, H 2021, 'Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension', Frontiers in Physiology, bind 12, 649668. https://doi.org/10.3389/fphys.2021.649668

APA

Ørntoft, N. W., Blé, M., Baiges, A., Ferrusquia, J., Hernández-Gea, V., Turon, F., Magaz, M., Møller, S., Møller, H. J., Garcia-Pagan, J. C., & Gronbaek, H. (2021). Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension. Frontiers in Physiology, 12, [649668]. https://doi.org/10.3389/fphys.2021.649668

CBE

Ørntoft NW, Blé M, Baiges A, Ferrusquia J, Hernández-Gea V, Turon F, Magaz M, Møller S, Møller HJ, Garcia-Pagan JC, Gronbaek H. 2021. Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension. Frontiers in Physiology. 12:Article 649668. https://doi.org/10.3389/fphys.2021.649668

MLA

Vancouver

Author

Ørntoft, Nikolaj Worm ; Blé, Michel ; Baiges, Anna ; Ferrusquia, Jose ; Hernández-Gea, Virginia ; Turon, Fanny ; Magaz, Marta ; Møller, Søren ; Møller, Holger Jon ; Garcia-Pagan, Juan Carlos ; Gronbaek, Henning. / Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension. I: Frontiers in Physiology. 2021 ; Bind 12.

Bibtex

@article{2f7b4e8d0f6c4f20ba7b16df3cd25df3,
title = "Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension",
abstract = "Introduction: Macrophages are involved in development and progression of chronic liver disease and portal hypertension. The macrophage activation markers soluble (s)CD163 and soluble mannose receptor (sMR), are associated with portal hypertension in patient with liver cirrhosis but never investigated in patients with non-cirrhotic portal hypertension. We hypothesized higher levels in cirrhotic patients with portal hypertension than patients with non-cirrhotic portal hypertension. We investigated sCD163 and sMR levels in patients with portal hypertension due to idiopathic portal hypertension (IPH) and portal vein thrombosis (PVT) in patients with and without cirrhosis.Methods: We studied plasma sCD163 and sMR levels in patients with IPH (n = 26), non-cirrhotic PVT (n = 20), patients with cirrhosis without PVT (n = 31) and with PVT (n = 17), and healthy controls (n = 15).Results: Median sCD163 concentration was 1.51 (95% CI: 1.24-1.83) mg/L in healthy controls, 1.96 (95% CI: 1.49-2.56) in patients with non-cirrhotic PVT and 2.16 (95% CI: 1.75-2.66) in patients with IPH. There was no difference between non-cirrhotic PVT patients and healthy controls, whereas IPH patients had significantly higher levels than controls (P < 0.05). The median sCD163 was significantly higher in the cirrhotic groups compared to the other groups, with a median sCD163 of 6.31 (95% CI: 5.16-7.73) in cirrhotics without PVT and 5.19 (95% CI: 4.18-6.46) with PVT (P < 0.01, all). Similar differences were observed for sMR.Conclusion: Soluble CD163 and sMR levels are elevated in patients with IPH and patients with cirrhosis, but normal in patients with non-cirrhotic PVT. This suggests that hepatic macrophage activation is more driven by the underlying liver disease with cirrhosis than portal hypertension.",
keywords = "portal hypertension, cirrhosis, macrophages, non-cirrhotic portal hypertension, biomarker",
author = "{\O}rntoft, {Nikolaj Worm} and Michel Bl{\'e} and Anna Baiges and Jose Ferrusquia and Virginia Hern{\'a}ndez-Gea and Fanny Turon and Marta Magaz and S{\o}ren M{\o}ller and M{\o}ller, {Holger Jon} and Garcia-Pagan, {Juan Carlos} and Henning Gronbaek",
note = "Copyright {\textcopyright} 2021 {\O}rntoft, Bl{\'e}, Baiges, Ferrusquia, Hern{\'a}ndez-Gea, Turon, Magaz, M{\o}ller, M{\o}ller, Garcia-Pagan and Gronbaek.",
year = "2021",
month = jun,
day = "11",
doi = "10.3389/fphys.2021.649668",
language = "English",
volume = "12",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension

AU - Ørntoft, Nikolaj Worm

AU - Blé, Michel

AU - Baiges, Anna

AU - Ferrusquia, Jose

AU - Hernández-Gea, Virginia

AU - Turon, Fanny

AU - Magaz, Marta

AU - Møller, Søren

AU - Møller, Holger Jon

AU - Garcia-Pagan, Juan Carlos

AU - Gronbaek, Henning

N1 - Copyright © 2021 Ørntoft, Blé, Baiges, Ferrusquia, Hernández-Gea, Turon, Magaz, Møller, Møller, Garcia-Pagan and Gronbaek.

PY - 2021/6/11

Y1 - 2021/6/11

N2 - Introduction: Macrophages are involved in development and progression of chronic liver disease and portal hypertension. The macrophage activation markers soluble (s)CD163 and soluble mannose receptor (sMR), are associated with portal hypertension in patient with liver cirrhosis but never investigated in patients with non-cirrhotic portal hypertension. We hypothesized higher levels in cirrhotic patients with portal hypertension than patients with non-cirrhotic portal hypertension. We investigated sCD163 and sMR levels in patients with portal hypertension due to idiopathic portal hypertension (IPH) and portal vein thrombosis (PVT) in patients with and without cirrhosis.Methods: We studied plasma sCD163 and sMR levels in patients with IPH (n = 26), non-cirrhotic PVT (n = 20), patients with cirrhosis without PVT (n = 31) and with PVT (n = 17), and healthy controls (n = 15).Results: Median sCD163 concentration was 1.51 (95% CI: 1.24-1.83) mg/L in healthy controls, 1.96 (95% CI: 1.49-2.56) in patients with non-cirrhotic PVT and 2.16 (95% CI: 1.75-2.66) in patients with IPH. There was no difference between non-cirrhotic PVT patients and healthy controls, whereas IPH patients had significantly higher levels than controls (P < 0.05). The median sCD163 was significantly higher in the cirrhotic groups compared to the other groups, with a median sCD163 of 6.31 (95% CI: 5.16-7.73) in cirrhotics without PVT and 5.19 (95% CI: 4.18-6.46) with PVT (P < 0.01, all). Similar differences were observed for sMR.Conclusion: Soluble CD163 and sMR levels are elevated in patients with IPH and patients with cirrhosis, but normal in patients with non-cirrhotic PVT. This suggests that hepatic macrophage activation is more driven by the underlying liver disease with cirrhosis than portal hypertension.

AB - Introduction: Macrophages are involved in development and progression of chronic liver disease and portal hypertension. The macrophage activation markers soluble (s)CD163 and soluble mannose receptor (sMR), are associated with portal hypertension in patient with liver cirrhosis but never investigated in patients with non-cirrhotic portal hypertension. We hypothesized higher levels in cirrhotic patients with portal hypertension than patients with non-cirrhotic portal hypertension. We investigated sCD163 and sMR levels in patients with portal hypertension due to idiopathic portal hypertension (IPH) and portal vein thrombosis (PVT) in patients with and without cirrhosis.Methods: We studied plasma sCD163 and sMR levels in patients with IPH (n = 26), non-cirrhotic PVT (n = 20), patients with cirrhosis without PVT (n = 31) and with PVT (n = 17), and healthy controls (n = 15).Results: Median sCD163 concentration was 1.51 (95% CI: 1.24-1.83) mg/L in healthy controls, 1.96 (95% CI: 1.49-2.56) in patients with non-cirrhotic PVT and 2.16 (95% CI: 1.75-2.66) in patients with IPH. There was no difference between non-cirrhotic PVT patients and healthy controls, whereas IPH patients had significantly higher levels than controls (P < 0.05). The median sCD163 was significantly higher in the cirrhotic groups compared to the other groups, with a median sCD163 of 6.31 (95% CI: 5.16-7.73) in cirrhotics without PVT and 5.19 (95% CI: 4.18-6.46) with PVT (P < 0.01, all). Similar differences were observed for sMR.Conclusion: Soluble CD163 and sMR levels are elevated in patients with IPH and patients with cirrhosis, but normal in patients with non-cirrhotic PVT. This suggests that hepatic macrophage activation is more driven by the underlying liver disease with cirrhosis than portal hypertension.

KW - portal hypertension

KW - cirrhosis

KW - macrophages

KW - non-cirrhotic portal hypertension

KW - biomarker

UR - http://www.scopus.com/inward/record.url?scp=85115753842&partnerID=8YFLogxK

U2 - 10.3389/fphys.2021.649668

DO - 10.3389/fphys.2021.649668

M3 - Journal article

C2 - 34177608

VL - 12

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

M1 - 649668

ER -

ID: 66508541